Free Trial
→ Do NOT Buy SpaceX – Do This Instead (From Stansberry Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Absci Corporation stock logo
ABSI
Absci
$10.33
+15.5%		$9.24
$2.24
▼
$12.06
$1.77B2.274.35 million shs2.65 million shs
Alkermes plc stock logo
ALKS
Alkermes
$40.72
+1.5%		$46.10
$27.00
▼
$55.67
$6.83B0.322.15 million shs871,142 shs
Immunovant, Inc. stock logo
IMVT
Immunovant
$30.50
+0.8%		$38.58
$16.59
▼
$45.42
$6.29B0.841.51 million shs529,155 shs
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
$45.42
+4.9%		$53.07
$42.63
▼
$86.74
$7.54B0.382.65 million shs3.10 million shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Absci Corporation stock logo
ABSI
Absci
-3.04%-16.84%+0.34%-15.66%+113.88%
Alkermes plc stock logo
ALKS
Alkermes
-3.21%-1.06%-11.83%-22.78%+27.29%
Immunovant, Inc. stock logo
IMVT
Immunovant
-5.56%-10.07%-23.53%-23.80%+88.18%
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
-1.95%-1.59%-23.65%-25.67%-38.11%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Absci Corporation stock logo
ABSI
Absci
$10.33
+15.5%		$9.24
$2.24
▼
$12.06
$1.77B2.274.35 million shs2.65 million shs
Alkermes plc stock logo
ALKS
Alkermes
$40.72
+1.5%		$46.10
$27.00
▼
$55.67
$6.83B0.322.15 million shs871,142 shs
Immunovant, Inc. stock logo
IMVT
Immunovant
$30.50
+0.8%		$38.58
$16.59
▼
$45.42
$6.29B0.841.51 million shs529,155 shs
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
$45.42
+4.9%		$53.07
$42.63
▼
$86.74
$7.54B0.382.65 million shs3.10 million shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Absci Corporation stock logo
ABSI
Absci
-3.04%-16.84%+0.34%-15.66%+113.88%
Alkermes plc stock logo
ALKS
Alkermes
-3.21%-1.06%-11.83%-22.78%+27.29%
Immunovant, Inc. stock logo
IMVT
Immunovant
-5.56%-10.07%-23.53%-23.80%+88.18%
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
-1.95%-1.59%-23.65%-25.67%-38.11%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Absci Corporation stock logo
ABSI
Absci
2.78
Moderate Buy$13.7135.42% Upside
Alkermes plc stock logo
ALKS
Alkermes
2.74
Moderate Buy$54.4733.59% Upside
Immunovant, Inc. stock logo
IMVT
Immunovant
2.58
Moderate Buy$44.0044.81% Upside
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
2.73
Moderate Buy$89.2097.56% Upside

Current Analyst Ratings Breakdown

Latest ABSI, IONS, ALKS, and IMVT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/2/2026
Immunovant, Inc. stock logo
IMVT
Immunovant
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/28/2026
Absci Corporation stock logo
ABSI
Absci
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
9/24/2026
Immunovant, Inc. stock logo
IMVT
Immunovant
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
9/24/2026
Immunovant, Inc. stock logo
IMVT
Immunovant
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingPositive
9/24/2026
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
Oppenheimer Holdings, Inc. logo
Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$85.00
9/24/2026
Alkermes plc stock logo
ALKS
Alkermes
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral$50.00
9/24/2026
Alkermes plc stock logo
ALKS
Alkermes
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold$50.00
9/24/2026
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$100.00
9/23/2026
Immunovant, Inc. stock logo
IMVT
Immunovant
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
9/23/2026
Absci Corporation stock logo
ABSI
Absci
Needham & Company LLC logo
Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$11.00
9/22/2026
Alkermes plc stock logo
ALKS
Alkermes
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$56.00
(Data available from 10/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Absci Corporation stock logo
ABSI
Absci
$2.80M620.68N/AN/A$1.26 per share8.04
Alkermes plc stock logo
ALKS
Alkermes
$1.48B4.63$1.65 per share24.75$11.02 per share3.70
Immunovant, Inc. stock logo
IMVT
Immunovant
N/AN/AN/AN/A$4.19 per shareN/A
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
$944M7.95N/AN/A$3.02 per share14.95
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Absci Corporation stock logo
ABSI
Absci
-$115.18M-$0.80N/AN/AN/A-7,756.38%-61.71%-54.52%11/16/2026 (Estimated)
Alkermes plc stock logo
ALKS
Alkermes
$241.66M$0.38107.16169.90N/A3.96%4.15%2.19%10/28/2026 (Estimated)
Immunovant, Inc. stock logo
IMVT
Immunovant
-$505.61M-$2.82N/AN/AN/AN/A-69.59%-62.49%11/9/2026 (Estimated)
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
-$381.39M-$3.46N/AN/AN/A-64.76%-111.08%-17.41%11/4/2026 (Estimated)

Latest ABSI, IONS, ALKS, and IMVT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/4/2026Q3 2026
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
-$1.21N/AN/AN/A$183.13 millionN/A
10/28/2026Q3 2026
Alkermes plc stock logo
ALKS
Alkermes
-$0.0796N/AN/AN/A$463.62 millionN/A
8/11/2026Q2 2026
Absci Corporation stock logo
ABSI
Absci
-$0.1910-$0.21-$0.0190-$0.21$0.92 million$0.32 million
8/6/2026Q1 2027
Immunovant, Inc. stock logo
IMVT
Immunovant
-$0.6289-$0.75-$0.1211-$0.75$7.10 million$7.10 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Absci Corporation stock logo
ABSI
Absci
N/AN/AN/AN/AN/A
Alkermes plc stock logo
ALKS
Alkermes
N/AN/AN/AN/AN/A
Immunovant, Inc. stock logo
IMVT
Immunovant
N/AN/AN/AN/AN/A
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Absci Corporation stock logo
ABSI
Absci
N/A
10.63
10.63
Alkermes plc stock logo
ALKS
Alkermes
0.82
2.30
1.85
Immunovant, Inc. stock logo
IMVT
Immunovant
N/A
7.27
7.27
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
3.07
7.89
7.73

Institutional Ownership

CompanyInstitutional Ownership
Absci Corporation stock logo
ABSI
Absci
52.05%
Alkermes plc stock logo
ALKS
Alkermes
95.21%
Immunovant, Inc. stock logo
IMVT
Immunovant
47.08%
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
93.86%

Insider Ownership

CompanyInsider Ownership
Absci Corporation stock logo
ABSI
Absci
10.52%
Alkermes plc stock logo
ALKS
Alkermes
4.59%
Immunovant, Inc. stock logo
IMVT
Immunovant
1.90%
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
1.81%
CompanyEmployeesShares OutstandingFree FloatOptionable
Absci Corporation stock logo
ABSI
Absci
140171.61 million153.56 millionOptionable
Alkermes plc stock logo
ALKS
Alkermes
2,050167.76 million160.06 millionOptionable
Immunovant, Inc. stock logo
IMVT
Immunovant
315206.55 million202.63 millionOptionable
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
1,402166.18 million163.18 millionOptionable

Recent News About These Companies

Ionis Pharmaceuticals (IONS) Stock Could Still Trade At A Premium Despite A 46% Slump
October 8 at 11:41 PM  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/news/ionis-pharmaceuticals-ions-stock-could-011513184.html
NVS Wins FDA Nod for Label Expansion of Immunology Drug Rhapsido
October 8 at 1:20 PM  |  zacks.comhttps://www.zacks.com/stock/news/3003077/nvs-wins-fda-nod-for-label-expansion-of-immunology-drug-rhapsido?cid=cs-stocknewsapi-ft-analyst_blog|company_news_medical_sector-3003077
Ionis Pharmaceuticals (NASDAQ:IONS) Sets New 1-Year Low - Time to Sell?
October 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31087462
Ionis Pharmaceuticals (NASDAQ:IONS) Reaches New 52-Week Low - Should You Sell?
October 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-ionis-pharmaceuticals-nasdaq-ions-reaches-new-52-week-low-should-you-sell-2026-10-05/
Consensus price target for Ionis Pharmaceuticals rises 20.88% to MX$1,849.62
October 2, 2026  |  msn.comhttps://www.msn.com/en-us/money/economy/consensus-price-target-for-ionis-pharmaceuticals-rises-20-88-to-mx-1-849-62/ar-AA2dr6vs
Critical Review: Alector (NASDAQ:ALEC) vs. Ionis Pharmaceuticals (NASDAQ:IONS)
October 1, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31073716
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Stock Rated "Moderate Buy" by Sell-Side Analysts
September 30, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31067943
4 RNA Therapeutics Stocks Leading the Next Wave of Innovation
September 28, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2996769/4-rna-therapeutics-stocks-leading-the-next-wave-of-innovation?cid=cs-stocknewsapi-ft-analyst_blog|investment_ideas-2996769
Reviewing Synlogic (NASDAQ:SYBX) & Ionis Pharmaceuticals (NASDAQ:IONS)
September 28, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31056452
Analysts Offer Insights on Healthcare Companies: NanoViricides (NNVC) and Ionis Pharmaceuticals (IONS)
September 25, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/IONS/pressreleases/4800676/analysts-offer-insights-on-healthcare-companies-nanoviricides-nnvc-and-ionis-pharmaceuticals-ions/
Oppenheimer Sticks to Its Buy Rating for Ionis Pharmaceuticals (IONS)
September 25, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/IONS/pressreleases/4798816/oppenheimer-sticks-to-its-buy-rating-for-ionis-pharmaceuticals-ions/
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Stock Has Average Price Target of $89.20 According to Brokerages
September 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-ionis-pharmaceuticals-inc-nasdaq-ions-stock-has-average-price-target-of-8920-according-to-brokerages-2026-09-25/
Ionis Pharmaceuticals (IONS) Stock Looks Pricey On Its 45% YTD Slide
September 24, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/ionis-pharmaceuticals-ions-stock-looks-001804914.html
Canaccord Genuity Remains a Buy on Ionis Pharmaceuticals (IONS)
September 24, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/IONS/pressreleases/4774312/canaccord-genuity-remains-a-buy-on-ionis-pharmaceuticals-ions/
Ionis Pharmaceuticals (NASDAQ:IONS) Receives "Buy" Rating from HC Wainwright
September 24, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-ionis-pharmaceuticals-nasdaq-ions-receives-buy-rating-from-hc-wainwright-2026-09-24/
Ionis Pharmaceuticals, Roche Say Kidney Disease Drug Candidate Meets Main Goal in Phase 3 Study
September 23, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/ionis-pharmaceuticals-roche-kidney-disease-075301108.html
Ionis announces positive interim data from partner Roche’s Phase 3 IMAgINATION study in IgA nephropathy (IgAN)
September 23, 2026  |  rutlandherald.comR
Ionis Delivers Positive Late-Stage Results for Two Partnered Drugs
September 23, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2994701/ionis-delivers-positive-late-stage-results-for-two-partnered-drugs?cid=cs-stocknewsapi-ft-analyst_blog|company_news_medical_sector-2994701
Ionis and Roche Advance First RNA-Targeted Therapy for Autoimmune Kidney Disease
September 23, 2026  |  benzinga.comhttps://www.benzinga.com/trading-ideas/movers/26/09/61942930/ionis-and-roche-advance-first-rna-targeted-therapy-for-autoimmune-kidney-disease?utm_source=snapi
Ionis announces positive interim data from partner Roche's Phase 3 IMAgINATION study in IgA nephropathy (IgAN)
September 23, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260922857250/en/ionis-announces-positive-interim-data-from-partner-roche%e2%80%99s-phase-3-imagination-study-in-iga-nephropathy-igan/
Ionis Pharmaceuticals, Inc. (IONS) Stock: Surges as Phase 3 ALS Trial Delivers Positive Results
September 22, 2026  |  blockonomi.comhttps://blockonomi.com/ionis-pharmaceuticals-inc-ions-stock-surges-as-phase-3-als-trial-delivers-positive-results/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Computer monitor with a red plunging chart arrow on a desk, symbolizing software stocks selloff amid AI fears.
MarketBeat's Most Downgraded Stocks in Q3: 2 Look Cheap, 1 Looks Risky
By Thomas Hughes | September 15, 2026
Bloom Energy fuel cell units installed outside a data center building labeled "AI" at dusk.
Can Bloom Energy Pop the Top Off AI’s Massive Energy Bottleneck?
By Thomas Hughes | September 21, 2026
A gold Bitcoin coin sits on a desk in a trading room with large screens displaying market data.
Why Bitcoin ETFs May Be Worth Another Look as Inflows Rebound
By Nathan Reiff | September 13, 2026
Illustration of the Braze logo at the center of a diagram connecting customer data icons to email, mobile, and messaging channels.
Braze Beat Expectations—Now 2 SaaS Peers Are in Focus
By Nathan Reiff | September 18, 2026
IonQ logo displayed against a dark background with glowing orange network nodes and geometric shapes.
IonQ and NVIDIA Just Cracked a Major Quantum Computing Bottleneck
By Jeffrey Neal Johnson | September 17, 2026
Absci stock logo

Absci NASDAQ:ABSI

$10.32 +1.38 (+15.38%)
As of 01:41 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington.

Alkermes stock logo

Alkermes NASDAQ:ALKS

$40.71 +0.60 (+1.49%)
As of 01:42 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Immunovant stock logo

Immunovant NASDAQ:IMVT

$30.50 +0.24 (+0.81%)
As of 01:42 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Ionis Pharmaceuticals stock logo

Ionis Pharmaceuticals NASDAQ:IONS

$45.45 +2.15 (+4.97%)
As of 01:41 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas